<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202408</url>
  </required_header>
  <id_info>
    <org_study_id>SKI2670_EMSD_I_2013</org_study_id>
    <nct_id>NCT02202408</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670</brief_title>
  <official_title>A Phase I, Double-blind, Randomized, Placebo-controlled, Single-Dose Escalation, First-in-human Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SKI2670</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase I study, the primary objective is to investigate the safety and tolerability of
      SKI2670 after oral administration in healthy female subjects. And secondary objective is to
      investigate the pharmacokinetics and pharmacodynamics of SKI2670 after oral administration in
      healthy female subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Phase I study, the primary objective is to investigate the safety and tolerability of
      SKI2670 after oral administration in healthy female subjects.

      Secondary objective is to investigate the pharmacokinetics and pharmacodynamics of SKI2670
      after oral administration in healthy female subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>From day 1 to day 16~26D after a single oral dose.</time_frame>
    <description>All participants who ever were administered with investigational product are assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of SKI2670</measure>
    <time_frame>0h(pre-dose), 10min, 20min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h</time_frame>
    <description>Peak Plasma Concentration (Cmax) of SKI2670</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) of SKI2670</measure>
    <time_frame>0h(pre-dose), 10min, 20min, 30min, 45min, 1h, 1.5h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 72h</time_frame>
    <description>Area Under Curve (AUC) of SKI2670</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration Change from Baseline(%) of Luteinizing Hormone (LH)</measure>
    <time_frame>day -1, 0h(pre-dose), 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 30h, 36h, 48h, 72h, day 7~12D, 16~26D</time_frame>
    <description>Concentration Change from Baseline(%) of Luteinizing Hormone (LH)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>SKI2670</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group
-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI2670</intervention_name>
    <description>Oral, Single Dose</description>
    <arm_group_label>SKI2670</arm_group_label>
    <other_name>N/A(only SKI2670)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Same shape as the experimental drug</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>N/A(only 1 Placebo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, 20 years of age and older

          2. Weight between 40kg~70kg

          3. Women who agreed using double contraception method and spermicide, avoiding
             breast-feeding for at least 30days after IP(investigational product) dosing

          4. A history of regular menstrual cycles (cycle: 28±7day, duration: 2~7day) for at least
             2 years and a positive ovulation test between day 11 and 21 in the preceding menstrual
             cycle of IP(investigational product) dosing

        Exclusion Criteria:

          1. Women who are pregnant or serum/urine hCG(human chorionic gonadotropin) positive or
             breast-feeding

          2. A history of breast cancer, genital cancer or any estrogen dependent tumor

          3. Specified or unspecified diagnosed infertility or history of natural abortion over
             three times

          4. A history of taking other Investigational product within 60days before screening visit
             or taking ETC drug(Ethical drugs), oriental medicine or OTC drugs(Over-the-Counter
             drugs) within 14days before screening visit

          5. Clinically significant Gynecological disease identified by ultrasonography including
             estrogen dependent tumor or lesion, sever inflammation or synechia

          6. AST(Aspartate aminotransferase), ALT(Alanine aminotransferase) ≥ 2.5 times the upper
             limit of normal

          7. QTc &gt; 450ms on electrocardiogram result
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center Department of Clinical Pharmacology and Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

